GDP方案治疗复发和难治性非霍奇金淋巴瘤的疗效观察

目的 观察GDP方案(吉西他滨、顺铂、地塞米松)治疗复发和难治性非霍奇金淋巴瘤(NHL)的疗效和不良反应.方法 回顾性分析用GDP方案治疗的19例复发和难治性非霍奇金淋巴瘤患者的临床资料,包括治疗后缓解情况、复发率、生存率以及出现的不良反应.结果 19例患者均可评价疗效和不良反应,其中完全缓解(CR)5例,部分缓解(PR)5例,稳定(SD)4例,进展(PD)3例,总有效率为52.6%.1年总生存率为48.8%.主要不良反应为骨髓抑制,其中Ⅲ~Ⅳ度中性粒细胞减少发生率为15.8%,Ⅲ~Ⅳ度血小板减少发生率为21.1%,恶心呕吐反应一般对症治疗可恢复,无治疗相关死亡.结论 GDP方案治疗难治和复发性非霍奇金淋巴瘤疗效好,副作用可以耐受,是一种值得进一步推广的挽救治疗方案.

Efficacy of GDP Regimen for Relapsed and Refractory Non-Hodgkin's Lymphoma

Objective To investigate the efficacy and adverse reactions of GDP regimen ( gemcitabine、cisplatin、dexam-ethasone) for relapsed and refractory non-Hodgkin's lymphoma (NHL).Methods A retrospective analysis of clinical data of 19 cases of relapsed and refractory non-Hodgkin's lymphoma patients treated with GDP regimen were conducted ,including the treat-ment of post-remission,relapse rate,survival,and adverse reactions .Results Efficacy and adverse reactions of 19 patients were evaluable,including complete remission (CR) 5 cases,partial remission (PR) 5 cases,stable (SD) 4 cases,progression (PD)3 cases,the total efficiency was 52.6%.1-year overall survival rate was 48.8%.The main side effects was myelosuppression ,the incidence rate of Ⅲ ~Ⅳ degree of neutropenia was 15.8%, the incidence rate of Ⅲ ~Ⅳ degree of thrombocytopenia was 21.1%,nausea and vomiting were generally recoverable symptom ,and there was no treatment-related deaths .Conclusion GDP regimen for refractory and relapsed non-Hodgkin's lymphoma is effective,side effects can be tolerated,and it is worthy of further promotion of a salvage regimen .